Tekla Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Tekla Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-50,538	Closed	-$5.42M	–	185
2023 Q1	$5.42M	Buy	50,538 +12,301	+32%	+$1.42M	0.21%	77
2022 Q4	$4.21M	Buy	38,237 +6,732	+21%	+$437K	0.16%	82
2022 Q3	$1.86M	Sell	31,505 -17,690	-36%	-$809K	0.08%	116
2022 Q2	$1.39M	Buy	49,195 +27,080	+122%	+$785K	0.05%	125
2022 Q1	$835K	Buy	+22,115	New	+$874K	0.03%	150

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Tekla Capital Management's RXDX Position: Q2 2023 in Review

Tekla Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 50,538 shares — an estimated $5.42M sold.

Tekla Capital Management first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $5.42M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Tekla Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Tekla Capital Management sold 50,538 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.42M.
Tekla Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Tekla Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $5.42M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.